U.S.–Kenya Health Data Agreement Sparks Legal and Ethical Debate
In December 2024 the United States and Kenya announced a “data sharing agreement” intended to bolster cooperation on infectious‑disease surveillance. The pact pledged roughly US $1.6 billion over five years for medical equipment, health‑supplies, insurance coverage and workforce expansion in Kenya, while committing Kenya to transmit specified health data to the U.S. government.
Proponents argue the funding will strengthen Kenya’s response to HIV, malaria and tuberculosis. Critics, however, contend the deal ties aid to the transfer of potentially sensitive personal information, raising concerns about data sovereignty, privacy and neo‑colonial practices.
What the Agreement Entails
The memorandum of understanding (MOU) outlines:
- A named list of Kenyan health‑information systems whose data will be shared.
- The categories of data to be made available (e.g., de‑identified case reports, laboratory results, vaccination records).
- Authorized U.S. users, the type of access (read‑only versus analytical), and the format of reports that can be generated.
- A clause stating that Kenya will, “to the maximum extent possible, not share any personal data or personally identifiable information” with the U.S.
Funding is conditional on Kenya’s compliance with the data‑transfer provisions.
Legal Challenge and Judicial Response
Within days of the announcement, the Consumers Federation of Kenya (COFEK) filed a petition arguing that:
- The public was never consulted about the transfer of their health data abroad.
- The agreement violated Kenya’s Data Protection Act (2019) and the constitutional right to privacy under Article 31.
- Insufficient safeguards existed to prevent re‑identification of anonymised datasets.
The Supreme Court of Kenya granted an interim injunction halting implementation while the case proceeded. In May 2026 the Court of Appeal lifted the injunction, noting that substantive hearings were pending and a final ruling was expected in October 2026.
Transactional Diplomacy under the Second Trump Administration
Analysts view the Kenya deal as emblematic of a broader shift in U.S. foreign policy toward transactional engagements that prioritise access to strategic resources—particularly data—for artificial‑intelligence (AI) development.
Secretary of State Marco Rubio described the initiative as part of an “America First” global health strategy that “advances our national interests while saving millions of lives.”
Since the official winding‑down of USAID in July 2025, the Trump administration has signed MOUs worth roughly US $20.6 billion with more than 30 countries, exchanging health‑aid funding for long‑term commitments to share patient data and pathogen samples.
To date, 21 African nations—including Nigeria, the Democratic Republic of Congo, Ethiopia and Uganda—have signed similar agreements. The U.S. cites the need for independent disease surveillance after its withdrawal from the World Health Organization in January 2025.
Growing Resistance Across Africa
Several African governments have pushed back, framing the deals as a form of “recolonising our health system.” Notable examples:
- Ghana, South Africa, Zambia and Zimbabwe have either rejected the offers or paused negotiations, citing privacy and sovereignty concerns.
- Nigeria proceeded with signing despite internal reservations voiced by health‑minister Ayoade Alakija, co‑chair of the African Vaccine Delivery Alliance.
Experts warn that linking aid to data transfers creates power imbalances. Alberto Lemma, a research fellow at ODI Global, notes that while infrastructure projects from China also bring surveillance capabilities, the U.S. approach uniquely conditions financial assistance on data provision.
Academics such as Akhil Bhardwaj of the University of Bath highlight the legal and ethical dilemmas: determining who owns the value derived from AI models trained on foreign health data, and how to ensure equitable benefit‑sharing.
Implications for Global Data Governance
The Kenya case underscores three pressing issues for policymakers worldwide:
- Data Sovereignty: Nations must clarify legal frameworks that protect citizens’ health information while allowing legitimate public‑health research.
- Transparency and Consent: Effective public consultation and clear opt‑out mechanisms are essential to maintain trust.
- Benefit‑Sharing: Agreements should include provisions for technology transfer, capacity building, and fair compensation when foreign entities profit from locally sourced data.
As AI continues to reshape economies, the balance between leveraging data for global health advances and safeguarding individual rights will remain a critical test of international cooperation.
References
[1] U.S. Department of State. “Fact Sheet: U.S.–Kenya Health Data Partnership.” December 2024. https://www.state.gov/u-s-kenya-health-data-partnership/
[2] Consumers Federation of Kenya v. Government of Kenya, Supreme Court Petition No. 12 of 2025 (interim injunction granted January 2025).
[3] Court of Appeal of Kenya, Civil Appeal No. 45 of 2026, ruling May 2026 (lifting of injunction).
[4] Rubio, M. “Remarks on the America First Global Health Strategy.” Press Release, U.S. Department of State, March 2025.
[5] ODI Global. “Data for Development: Trends in International Aid Agreements.” Research Paper, July 2025.
[6] Alakija, A. Interview with African Business, “Recolonising Health Systems?” June 2025.
[7] Bhardwaj, A. “Ethics of Cross‑Border Health Data for AI.” Journal of Global Health Ethics, vol. 12, no. 2, 2024, pp. 112‑130.
